Methastyridone: Difference between revisions
CSV import |
CSV import |
||
| Line 27: | Line 27: | ||
[[Category:Withdrawn drugs]] | [[Category:Withdrawn drugs]] | ||
{{Pharma-stub}} | {{Pharma-stub}} | ||
<gallery> | |||
File:Methastyridone.svg|Methastyridone | |||
</gallery> | |||
Latest revision as of 01:18, 20 February 2025
Methastyridone is a pharmaceutical drug that was previously used in the treatment of psychiatric disorders. It is a thioxanthene derivative and is classified as a typical antipsychotic. Methastyridone was withdrawn from the market due to its potential to cause serious side effects.
History[edit]
Methastyridone was first synthesized in the 1960s as part of a series of thioxanthene derivatives. It was marketed under the brand name Rondar by the pharmaceutical company Janssen Pharmaceutica. However, it was withdrawn from the market in the 1970s due to concerns about its safety profile.
Pharmacology[edit]
As a thioxanthene derivative, methastyridone acts as a dopamine antagonist, blocking the action of dopamine in the brain. This can help to reduce symptoms of psychosis, but can also lead to side effects such as extrapyramidal symptoms and tardive dyskinesia.
Side Effects[edit]
The side effects of methastyridone can be severe and potentially life-threatening. These can include neuroleptic malignant syndrome, a rare but serious condition that can cause fever, muscle stiffness, and altered mental status. Other side effects can include akathisia, a feeling of restlessness, and dystonia, abnormal muscle movements.
Withdrawal[edit]
Methastyridone was withdrawn from the market due to its potential to cause serious side effects. The decision to withdraw the drug was made by Janssen Pharmaceutica in the 1970s, and it is no longer available for use.
See Also[edit]
-
Methastyridone
